Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in the USA / NCT07211646
Active, not recruiting Not applicable

The Assessment of Human Sleep and Its Functions

NCT07211646 · tracked via the Priya Life Science USA tracker
Sponsor
StimScience Inc
Phase
Not applicable
Started
2019-05-20
Last updated
2025-10-08

Condition(s) studied

Insomnia

Investigational drug(s) / intervention(s)

sham tESFixed tESPersonalized tES

sham tES: short 30s sham stimulation

Fixed tES: Fixed stimulation parameters for all participants

Personalized tES: Stimulation parameters personalized for each participant

Study summary

The purpose of this study is to look at the effects of targeted brain stimulation when falling asleep and on sleep quality.

Eligibility

Sex
ALL
Min age
18 Years
Max age
75 Years
Healthy volunteers
Accepted
Inclusion Criteria: * 18-75 year olds Exclusion Criteria: * Epilepsy * Seizure History * Serious head injury or brain surgery * Migraines * Metal implants in head * Pacemaker or implanted devices * Pregnancy * Any serious medical condition other than insomnia

Primary outcome measure(s)

  • Sleep Efficiency Change — up to 6 weeks
    Sleep efficiency (time slept as a percentage time spent in bed) changes across the different interventions for each subject and aggregate that across subjects
  • Sleep Onset Change — 1 day to 6 weeks
    Changes in time to fall asleep across the different interventions for each subject and aggregate that across subjects

Trial sites (1)

FacilityCityRegionStatus
StimScience Berkeley California

Other trials for the same condition

ASV Therapy for Insomnia Recruiting
Neurotechnology Following Traumatic Brain Injury Active, not recruiting
Evaluation of a Neurostimulation Device for Insomnia: A Randomized Trial Active, not recruiting
Remote STATE Training for Insomnia in Older Adults Active, not recruiting
Evaluation of Digital Sleep Program to Improve Sleep Among New Parents Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07211646 on ClinicalTrials.gov ↗ ← All trials in the USA